Trials / Completed
CompletedNCT00661609
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD4877 | Intravenous (IV)25mg/weekly |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-05-01
- Completion
- 2009-12-01
- First posted
- 2008-04-18
- Last updated
- 2011-01-12
- Results posted
- 2011-01-12
Locations
36 sites across 5 countries: United States, Canada, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00661609. Inclusion in this directory is not an endorsement.